Abstract
The inhibition of α-glucosidase and α-amylase, enzymes involved in the digestion of carbohydrates, can significantly reduce the post-prandial increase of blood glucose and therefore can be an important strategy in the management of blood glucose level in type 2 diabetic and borderline patients. Currently, there is renewed interest in plant-based medicines and functional foods modulating physiological effects in the prevention and cure of diabetes and obesity. The plant kingdom is a wide field to search for natural effective oral hypoglycaemic agents that have slight or no side effects. More than ca. 1200 plant species have been recorded to be used empirically worldwide for their alleged hypoglycaemic activity. Therefore, natural α-glucosidase and α-amylase inhibitors from plant sources offer an attractive strategy for the control of hyperglycaemia. This article reviews recent data on plant extracts and isolated natural compounds that are being tested for their hypoglycaemic activity, highlights ongoing research and considers the future perspectives.
Keywords: Diabetes, Post-prandial Hyperglycaemia, α-Glucosidase, α-Amylase, Extract, Natural compounds
Mini-Reviews in Medicinal Chemistry
Title: Natural Products as α-Amylase and α-Glucosidase Inhibitors and their Hypoglycaemic Potential in the Treatment of Diabetes: An Update
Volume: 10 Issue: 4
Author(s): R. Tundis, M.R. Loizzo and F. Menichini
Affiliation:
Keywords: Diabetes, Post-prandial Hyperglycaemia, α-Glucosidase, α-Amylase, Extract, Natural compounds
Abstract: The inhibition of α-glucosidase and α-amylase, enzymes involved in the digestion of carbohydrates, can significantly reduce the post-prandial increase of blood glucose and therefore can be an important strategy in the management of blood glucose level in type 2 diabetic and borderline patients. Currently, there is renewed interest in plant-based medicines and functional foods modulating physiological effects in the prevention and cure of diabetes and obesity. The plant kingdom is a wide field to search for natural effective oral hypoglycaemic agents that have slight or no side effects. More than ca. 1200 plant species have been recorded to be used empirically worldwide for their alleged hypoglycaemic activity. Therefore, natural α-glucosidase and α-amylase inhibitors from plant sources offer an attractive strategy for the control of hyperglycaemia. This article reviews recent data on plant extracts and isolated natural compounds that are being tested for their hypoglycaemic activity, highlights ongoing research and considers the future perspectives.
Export Options
About this article
Cite this article as:
Tundis R., Loizzo M.R. and Menichini F., Natural Products as α-Amylase and α-Glucosidase Inhibitors and their Hypoglycaemic Potential in the Treatment of Diabetes: An Update, Mini-Reviews in Medicinal Chemistry 2010; 10 (4) . https://dx.doi.org/10.2174/138955710791331007
DOI https://dx.doi.org/10.2174/138955710791331007 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot Topic:Modifying Cardiovascular Risk Factors: Newer Insights and Preventive Measures (Executive Editor: Aurelio Leone)]
Current Pharmaceutical Design Crosstalk between Oxidative and Nitrosative Stress and Arterial Stiffness
Current Vascular Pharmacology NAD+, Sirtuins, and Cardiovascular Disease
Current Pharmaceutical Design Formulation and Evaluation of Extended Release Asymmetric Membrane Capsules of Atenolol
Current Drug Delivery Dehydrogenases/Reductases for the Synthesis of Chiral Pharmaceutical Intermediates
Current Organic Chemistry Asymptomatic Lone Atrial Fibrillation - How can we Detect the Arrhythmia?
Current Pharmaceutical Design Women’s Ginseng (Angelica sinensis): An Ethnopharmacological Dossier
Current Traditional Medicine Antihypertensive Drugs Metabolism: An Update to Pharmacokinetic Profiles and Computational Approaches
Current Pharmaceutical Design Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer’s Disease
Current Alzheimer Research Serum Creatinine vs. Albuminuria as Biomarkers for the Estimation of Cardiovascular Risk
Current Vascular Pharmacology Editorial (Hot Topics: New Insights in the Pathogenesis and Treatment of Diabetic Retinopathy)
Current Medicinal Chemistry Craniofacial Fibrous Dysplasia Involvements of Mccune-Albright Syndrome: A Review with an Additional Case
Current Medical Imaging Role of Oxidative Stress in Development of Cardiovascular Complications in Diabetes Mellitus
Current Vascular Pharmacology Practical Application of Antidiabetic Efficacy of <i>Lycium barbarum</i> Polysaccharide in Patients with Type 2 Diabetes
Medicinal Chemistry Optimal Sedation for the Ventilation of Critically Ill Patients
Current Respiratory Medicine Reviews Amphetamine-Type Medicines: A Review of Pharmacokinetics, Pharmacodynamics, and Toxicological Aspects.
Current Clinical Pharmacology Sunitinib in the Treatment of Thyroid Cancer
Current Medicinal Chemistry Pentraxins: CRP and PTX3 and Cardiovascular Disease
Inflammation & Allergy - Drug Targets (Discontinued) Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review
Current Vascular Pharmacology Synthesis and Biological Activity of 3-(substitutedphenyl)- 6-(4-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)